Laboratory Procedure

Regeneron to Acquire 23andMe Out of Bankruptcy for $256 Million

3 weeks ago talkbio0Tagged Acquisition, Bankruptcy, data privacy, Genetic testing for cancer risk, Genome, personal genome service, Purchased Services, Clinical and Biomedical, Research, Regeneron, total health

Regeneron; 23andMe; acquisition; bankruptcy; genetic testing; genome; personal genome service; total health; research services; data privacy

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

3 weeks ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

1 month ago talkbio0Tagged Administration occupational activities, Albert, Bourla, chain concerns, Evaluation, Investments, Manufacturing, National Security, pharmaceutical tariffs, Policy, Sectioning technique, TNFRSF19 gene, Transplant Registry Unified Management Program

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns

France pauses chikungunya vaccinations in the elderly after patient death

1 month ago talkbio0Tagged Adverse event, Age, Chikungunya Fever, Disease Outbreaks, Elderly (population group), France, Latex Fixation Tests, older, Reunion Island, Vaccination, Vaccines

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

2 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU

2 months ago talkbio0Tagged drug price, EU, Industry, Investments, Pharma, Policy, Transplant Registry Unified Management Program, United States

EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price

U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs

2 months ago talkbio0Tagged Evaluation, global supply chain, Impact food supplement, Import, Manufacturing, pharmaceutical ingredients, pharmaceutical tariffs, Policy, regulatory, reshoring, Sectioning technique, supply chain exposure, TNFRSF19 gene, United States

U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact